Trading
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Good Morning $CBDW
Paid bashers giving away shares .. load zee boat
Shaking bashers out of their shares!! $CBDW
Gaurav ChandraGaurav Chandra
• 3rd+ • 3rd+
Chairman and CEO Adnexus Biotechnologies, Inc..An expert in Artificial Intelligence and a strong advocate of AI-empowered technology in drug discovery and its transformative power.Chairman and CEO Adnexus Biotechnologies, Inc..An expert in Artificial Intelligence and a strong advocate of AI-empowered technology in drug discovery and its transformative power.
2mo • 2 months ago
Follow
We are excited to share our vision and to introduce the passionate individuals leading our scientific endeavors. We are thrilled to reveal the outstanding drug production capabilities of our cutting-edge AI Drug Discovery platform. Additionally, we are proud to announce the launch of our website. As we begin this transformative journey, I'm reminded of a quote by Marie Curie: "Nothing in life is to be feared; it is only to be understood." Our team is dedicated to exploring uncharted territories in drug discovery, uncovering hidden biomarkers, and advancing our understanding of health and longevity. We are committed to turning our ideas into concrete cures and therapies by embracing innovation, vision, and scientific rigor. We recognize the significance of this work and are devoted to making a positive impact on the lives of others.
The Good Dr. Chandra ! With over 24 years of experience in healthcare, clinical research, and biotechnology, Dr. Chandra is a visionary leader and innovator in the field of infectious diseases. He is the chairman and CEO of Adnexus Inc, a company dedicated to combating various viruses by developing monoclonal antibodies, diagnostics, therapeutics, and vaccines.
Dr. Chandra and his team leverage artificial intelligence (AI) and drug discovery platforms to identify numerous drugs with diverse targets and applications, aiming to positively impact the world. Dr. Chandra has a profound understanding of both the clinical and scientific aspects of infectious diseases and the business and management aspects of the healthcare industry. He is a prolific writer and speaker who is passionate about AI and its potential to transform humanity. Dr. Chandra's mission is to lead the charge against infectious diseases through innovation and leadership.
Sutra™ - Levelling Up AI Research & Technology
Adnexus is proud to introduce and implement the latest Artificial Intelligence innovations in research and development technology – keeping the company at the forefront of early drug discovery and development and other revolutionary discoveries critical to the treatment of infectious diseases.
It is nice to light the fuse so they help get us on breakout boards for sure lmao $CBDW
Bashers with free shares have no clue about trading. $CBDW
Loving the volume and the bashers shakin shares
Considering these bashers (not on iHub speaking mostly about X/Twitter) do not appear to have day jobs, I would say cash is not unimaginable, if paid in shares I hope they are renegotiating that contract hahahaha.
Chandra is the best! 100% $CBDW
Artificial Intelligence Drug Discovery (AIDD) player in the ever-changing world of biotechnology. By leveraging the power of artificial intelligence (AI) to pioneer revolutionary advancements in the industry, Adnexus Biotechnology Inc. is reshaping how new therapies against validated and novel targets and solutions are uncovered, developed, and deployed to the market.
Shaking bashers out of their shares is a rare talent to have $CBDW
Doing more DD
Whats the SS?
Looks good here
Adnexus Biotechnology Inc. is making waves as a groundbreaking Artificial Intelligence Drug Discovery (AIDD) player in the ever-changing world of biotechnology. By leveraging the power of artificial intelligence (AI) to pioneer revolutionary advancements in the industry, Adnexus Biotechnology Inc. is reshaping how new therapies against validated and novel targets and solutions are uncovered, developed, and deployed to the market.
Pioneering AI in Biotechnology
$CBDW 's strategic focus on AI-driven, customer-centric solutions and services combined with a scalable SaaS model positions it well for substantial growth and success in the dynamic digital marketplace.
1606 Corp. represents a compelling investment opportunity, with its innovative solutions for the high-growth, multi-billion-dollar AI industry, strong market positioning, and commitment to sustainable and ethical business practices. The Company's strategic focus on AI-driven, customer-centric solutions and services combined with a scalable SaaS model positions it well for substantial growth and success in the dynamic digital marketplace. With the global AI market expanding rapidly, 1606 Corp.'s involvement in this sector positions it to leverage emerging trends and meet the evolving needs of the online CBD industry. The combination of technological leadership, market adaptability, and a SaaS business model makes 1606 Corp. an attractive prospect for investors looking to capitalize on the intersection of AI technology and e-commerce.
Event information:
When October 10, 2024 4:15 PM Eastern Time (US and Canada)
Register Here
Key Points
AI-driven customer service solutions
Addresses current consumer challenges
Revolutionizing customer service through AI technology
Approach enhances customer satisfaction and loyalty, leading to increased sales and a solid reputation in the digital marketplace
Addressing large market opportunity
Global AI market valued at $428 billion in 2022 with projections of reaching $2.25 trillion by 2030
Strong growth potential
Monthly licensing model / ChatBots as a SaaS solution
Highly scalable platform offers predictable revenue streams
Plans to adapt technology to various e-commerce sectors
Experienced team
Multidisciplinary team is well-equipped to tackle emerging challenges and drive the company forward
You think everyday should be green huh? You do know how stocks work .. right?
For more information on Adnexus read our latest blog belowhttps://t.co/loO12P7BjG
— CBDW.ai | A Brand by 1606 Corp (@CBDWInc) September 19, 2024
Nice 500k share buy $CBDW
Low floaters move easy. You know this .. you have been here for years. #HODL
Loaded a few more on this healthy pullback! $CBDW
Good Morning $CBDW
See if we can crack 04's here today #LFG $CBDW
1606 Corp. (OTC: CBDW) Investor Group Call
Join CEO Austin Lambrecht, for a presentation and live Q&A session. Learn about 1606 Corp.'s innovative solutions for the high-growth, multi-billion-dollar AI industry, strong market positioning, and commitment to sustainable and ethical business practices.
Event information:
When October 10, 2024 4:15 PM Eastern Time (US and Canada)
Good Morning $CBDW
Trying to get .04's here $CBDW
Bids building.. $CBDW
Take a look at the latest news this morning from the company.https://t.co/qne9GnhDRg
— CBDW.ai | A Brand by 1606 Corp (@CBDWInc) September 17, 2024
.0394 HOD .. close $CBDW
.04's up next! $CBDW Low Float Monster!!
The #AI platform utilizes a repository containing data on 19 viruses, a curated library of 8 million molecules, and human microbiome samples. The goal is to create robust models and make significant advancements in producing groundbreaking drugs that demonstrate effectiveness and disrupt the landscape of treatments for infectious and neurological diseases.
AI-Driven Drug Discovery $CBDW
Dr. Gaurav Chandra, expressing his enthusiasm about the strategic partnership with 1606 Corp. and emphasizing its significance, stated, "We are thrilled to embark on this strategic partnership with 1606 Corp. Their commitment to leveraging AI technology aligns perfectly with our mission to drive breakthroughs in drug discovery and infectious disease treatment. This collaboration represents a significant opportunity to enhance our technological capabilities and expand the impact of our innovative solutions."